The mind effortlessly performs approximation but is not to be trusted with the details.

5/I am excited that @KernelCo is combining its state-of-the-art neuroimaging with @CybinInc , a novel-molecule and psychedelic research company who is exploring the cutting edge of these exciting therapies.

3/which means that few pay to scan a patient’s brain, which means that there isn’t enough data to discover possible biomarkers, which means R&D departments have nothing to go on, which means few scans of brains, which means there won’t be any biomarkers discovered, which means...

4/Excitingly, the FDA has recently taken a new look at old-school psychedelics, allowing research on psychedelic pharmaceuticals as “breakthrough therapies” such as MDMA for PTSD and psilocybin and a variant of ketamine for resistant depression.

2/Why is this a trend across the largest pharma companies? In part, because of how hard it is to assess whether a new drug works in the brain when the endpoints are so subjective. There simply aren’t biomarkers or brain scan anomalies that we know of for many mental dysfunctions

1/Neuroscience is hard.

Pfizer, in 2018: “We have made the decision to end our neuroscience discovery and early development efforts...”

AmGen, in 2019: “...we've made the decision to end our neuroscience research and early development programs…”

the adornment on our new @KernelCo apparel

Gabe Newell of @valvesoftware - a future is fast approaching where video games will use data from people's brain signals to adjust the experience they get — and even a future where people's minds can be adjusted by computers.

Mental health is forgotten until it's the only thing that matters.